HIV Emergency Relief Project Grants

The purpose of this program is to provide direct financial assistance to an eligible metropolitan area (EMA) or a transitional grant area (TGA) that has been severely affected by the HIV epidemic. Grant funds assist eligible jurisdictions to devel

The purpose of this program is to provide direct financial assistance to an eligible metropolitan area (EMA) or a transitional grant area (TGA) that has been severely affected by the HIV epidemic. Grant funds assist eligible jurisdictions to develop or enhance access to a comprehensive, high quality, community-based care for people with HIV through the provision of grant funds. The goal is to provide optimal HIV care and treatment for people with HIV and improve their medical outcomes.

Eligible applicants are: State (includes District of Columbia, public institutions of higher education and hospitals), Local (includes State-designated lndian Tribes, excludes institutions of higher education and hospitals, Public nonprofit institution/organization (includes institutions of higher education and hospitals), Other public institution/organization, Federally Recognized lndian Tribal Governments, U.S. Territories and possessions (includes institutions of higher education and hospitals), Private nonprofit institution/organization (includes institutions of higher education and hospitals) RWHAP Part A recipients that were classified as an EMA or as a TGA in fiscal year (FY) 2007 and continue to meet the statutory requirements are eligible to apply for these funds; new areas that meet the threshold requirements are also eligible. For an EMA, this is more than 2,000 cases of AIDS reported and confirmed during the most recent five calendar years, and for a TGA, this is at least 1,000, but fewer than 2,000 cases of AIDS reported and confirmed during the most recent period of five calendar years for which such data are available. Additionally, they must not have fallen below, for three consecutive years, the required incidence levels already specified AND required prevalence levels (cumulative total of living cases of AIDS reported to and confirmed by the Director of the Centers for Disease Control and Prevention (CDC) as of December 31 of the most recent calendar year for which such data are available). For an EMA, this is 3,000 living cases of AIDS, and for a TGA, this is 1,500 living cases of AIDS, except certain areas which have a cumulative total of at least 1,400 living cases of AIDS and which have no more than 5 percent of the total from formula grants awarded unobligated as of the end of the most recent fiscal year. Eligible metropolitan areas (EMA) with a population of 50,000 or more individuals for which the CDC has reported a cumulative total of more than 2,000 AIDS cases for the most recent period of 5 calendar years include: Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Dallas, Texas; Detroit, Michigan, Ft. Lauderdale, Florida; Houston, Texas; Los Angeles, California; Miami, Florida; Nassau/Suffolk Counties, New York; New Haven, Connecticut; New Orleans, Louisiana; New York, New York; Newark, New Jersey; Orlando, Florida; Philadelphia, Pennsylvania; Phoenix, Arizona; San Diego, California; San Francisco, California; San Juan, Puerto Rico; Tampa-St. Petersburg, Florida; Washington, DC; and West Palm Beach, Florida. Transitional Grant areas (TGA) with a population of 50,000 or more individuals for which the CDC has reported a cumulative total of at least 1,000, but not more than 1,999 AIDS cases for the more most recent five year period include: Austin, Texas; Baton Rouge, Louisiana; Bergen-Passaic, New Jersey; Charlotte, North Carolina; Cleveland, Ohio; Columbus, Ohio; Denver, Colorado; Fort Worth, Texas; Hartford, Connecticut; Indianapolis, Indiana; Jacksonville, Florida; Jersey City, New Jersey; Kansas City, Missouri; Las Vegas, Nevada; Memphis, Tennessee; Middlesex, New Jersey; Minneapolis, Minnesota; Nashville, Tennessee; Norfolk, Virginia; Oakland, California; Orange County, California; Portland, Oregon; Riverside-San Bernardino, California; Sacramento, California; St. Louis, Missouri; San Antonio, Texas; San Jose, California; and Seattle, Washington.

Individual/Family, Physically Afflicted (e.g. TB, Arthritis, Heart Disease), Other Urban Individuals and families living with HIV disease.

Not less than 75 percent of grant funds remaining after reserving funds for administration and clinical quality management must be used to provide core medical services. Core medical services include: AIDS Drug Assistance Program Treatments, AIDS Pharmaceutical Assistance, Early Intervention Services, Health Insurance Premium and Cost Sharing Assistance for Low-Income Individuals, Home and Community-Based Health Services, Home Health Care, Hospice, Medical Case Management (including treatment adherence services), Medical nutritional Therapy, Mental Health Services, Oral Health Care, Outpatient/Ambulatory Health Services, Substance Abuse Outpatient Care. The remaining 25 percent may be used for support services, including: Child Care Services, Emergency Financial Assistance, Food Bank/Home Delivered Meals, Health Education/Risk Reduction, Housing, Legal Services, Linguistic Services, Medical Transportation, Non-Medical Case Management Services, Outreach Services, Permanency Planning, Psychosocial Support Services, Referral for Health Care and Support Services, Rehabilitation Services, Respite Care, and Substance Abuse Services (residential) that support a person with HIV to achieve better health outcomes. An EMA/TGA shall use a percentage of the grant, determined by the percentage of women, infants, children, and youth with HIV/AIDS in the jurisdiction, to provide core medical and support services to infants, children, youth, and women with HIV. Funds may not be used to make payments for any item or service to the extent that payment has been made, or can reasonably be expected to be made, with respect to that item or service under any State compensation program, insurance policy, Federal or State health benefits program or by any entity that provides health services on a prepaid basis (except for a program administered by or providing the services to the Indian Health Service). Funds may not be used to purchase or improve land, or to purchase, construct or make permanent improvement to any building except for minor remodeling. Funds may not be used to make cash payments to intended recipients of Ryan White HIV/AIDS Program (RWHAP) services. Funds may not be used for pre-exposure prophylaxis (PrEP) or non-occupational post-exposure prophylaxis (nPEP) medications or the related medical services, as outlined in the June 22, 2016 Program Letter. Additionally, the purchase of sterile needles or syringes for the purposes of hypodermic injection of any illegal drug is not allowable. Some aspects of Syringe Services Programs are allowable with HRSA's prior approval and in compliance with HHS and HRSA policy (see: https://www.hiv.gov/federal-response/policies-issues/syringe-services-programs). An EMA/TGA may not use more than 10 percent of amounts received under this grant for administration. Clinical Quality Management expenditures are not included in the administrative costs but are subject to a cap of the lesser of five percent of amounts received under the grant or $3,000,000. In addition, the aggregate total of administrative expenditures for subrecipients, including all indirect costs, may not exceed 10 percent of the aggregate amount of all subawards.

Not less than 75 percent of grant funds remaining after reserving funds for administration and clinical quality management must be used to provide core medical services. Core medical services include: AIDS Drug Assistance Program Treatments, AIDS Pharmaceutical Assistance, Early Intervention Services, Health Insurance Premium and Cost Sharing Assistance for Low-Income Individuals, Home and Community-Based Health Services, Home Health Care, Hospice, Medical Case Management (including treatment adherence services), Medical nutritional Therapy, Mental Health Services, Oral Health Care, Outpatient/Ambulatory Health Services, Substance Abuse Outpatient Care. The remaining 25 percent may be used for support services, including: Child Care Services, Emergency Financial Assistance, Food Bank/Home Delivered Meals, Health Education/Risk Reduction, Housing, Legal Services, Linguistic Services, Medical Transportation, Non-Medical Case Management Services, Outreach Services, Permanency Planning, Psychosocial Support Services, Referral for Health Care and Support Services, Rehabilitation Services, Respite Care, and Substance Abuse Services (residential) that support a person with HIV to achieve better health outcomes. An EMA/TGA shall use a percentage of the grant, determined by the percentage of women, infants, children, and youth with HIV/AIDS in the jurisdiction, to provide core medical and support services to infants, children, youth, and women with HIV. Funds may not be used to make payments for any item or service to the extent that payment has been made, or can reasonably be expected to be made, with respect to that item or service under any State compensation program, insurance policy, Federal or State health benefits program or by any entity that provides health services on a prepaid basis (except for a program administered by or providing the services to the Indian Health Service). Funds may not be used to purchase or improve land, or to purchase, construct or make permanent improvement to any building except for minor remodeling. Funds may not be used to make cash payments to intended recipients of Ryan White HIV/AIDS Program (RWHAP) services. Funds may not be used for pre-exposure prophylaxis (PrEP) or non-occupational post-exposure prophylaxis (nPEP) medications or the related medical services, as outlined in the June 22, 2016 Program Letter. Additionally, the purchase of sterile needles or syringes for the purposes of hypodermic injection of any illegal drug is not allowable. Some aspects of Syringe Services Programs are allowable with HRSA's prior approval and in compliance with HHS and HRSA policy (see: https://www.hiv.gov/federal-response/policies-issues/syringe-services-programs). An EMA/TGA may not use more than 10 percent of amounts received under this grant for administration. Clinical Quality Management expenditures are not included in the administrative costs but are subject to a cap of the lesser of five percent of amounts received under the grant or $3,000,000. In addition, the aggregate total of administrative expenditures for subrecipients, including all indirect costs, may not exceed 10 percent of the aggregate amount of all subawards.

Grants are awarded for a 12-month budget period, within a three-year period of performance.

Preapplication coordination is required. Environmental impact information is not required for this program. This program is eligible for coverage under E.O. 12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review. An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review.

Applications for supplemental funds must meet the review criteria outlined in the Notice of Funding Opportunity for the applicable period of performance.

Two-thirds of the funds available are disbursed on a formula basis as required by legislation, subject to a completeness review of required information specified in the HRSA NOFO issued under this CFDA program. The remaining one-third of available funds are disbursed as a competitive, supplemental grant, based on criteria specified by the legislation. All qualified applications will be forwarded to an objective review committee. Based on the recommendations of the objective review committee, the HRSA program official with delegated authority is responsible for final selection and funding decisions. In addition, Minority AIDS Initiative (MAI) funds available under Section 2693 of the Public Health Service Act are disbursed on a formula basis together with the Formula and Supplemental awards as required by the legislation. Notification is made in writing by a Notice of Award (NOA).

Approximately 6 months.